Oncotype DX
Oncotype DX, is a multi-gene assay that quantifies the likelihood of disease reoccurring in women with early-stage breast cancer. It also assesses the likely benefit from chemotherapy. Oncotype DX was developed and clinically validated by Genomic Health for women with early-stage breast cancer who are ER+ (estrogen receptor positive) and whose lymph nodes are negative.
Oncotype DX analyses a panel of 21 genes within a tumour to determine a Recurrence Score. The Recurrence Score is a number between 0 and 100 that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis. With this information, it may be possible for doctors and patients to make more informed decisions about breast cancer treatment options.
Beginning in 2009, Healthscope Pathology became a partner of Genomic Health, and can now assist both patients and doctors with Oncotype DX testing.
For further information on Oncotype DX click on the following links.
www.oncotypedx.com or www.mytreatmentdecision.com
Ordering Oncotype DX
For information on how to order Oncotype DX, please contact our product specialists on 0424 750 403 or 0402 563 020 or email: oncotype@healthscope.com.au
| Medicare Rebate available: | No, this test is not covered by Medicare |
| Specimen Type required: | The test is performed on a small amount of your tumour tissue that was removed during your original operation |
| Results available from your Doctor: | 10 - 14 days once the sample arrives at the Genomic Health laboratory |